Literature DB >> 24933225

Triptolide: progress on research in pharmacodynamics and toxicology.

Xiao-Jiaoyang Li1, Zhen-Zhou Jiang2, Lu-yong Zhang3.   

Abstract

ETHNOPHARMACOLOGICAL RELEVANCE: Tripterygium wilfordii Hook. f. (Tripterygium wilfordii), also known as Huangteng and gelsemium elegan, is a traditional Chinese medicine that has been marketed in China as Tripterygium wilfordii glycoside tablets. Triptolide (TP), an active component in Tripterygium wilfordii extracts, has been used to treat various diseases, including lupus, cancer, rheumatoid arthritis and nephritic syndrome. This review summarizes recent developments in the research on the pharmacodynamics, pharmacokinetics, pharmacy and toxicology of TP, with a focus on its novel mechanism of reducing toxicity. This review provides insight for future studies on traditional Chinese medicine, a field that is both historically and currently important.
MATERIALS AND METHODS: We included studies published primarily within the last five years that were available in online academic databases (e.g., PubMed, Google Scholar, CNKI, SciFinder and Web of Science).
RESULTS: TP has a long history of use in China because it displays multiple pharmacological activities, including anti-rheumatism, anti-inflammatory, anti-tumor and neuroprotective properties. It has been widely used for the treatment of various diseases, such as rheumatoid arthritis, nephritic syndrome, lupus, Behcet׳s disease and central nervous system diseases. Recently, numerous breakthroughs have been made in our understanding of the pharmacological efficacy of TP. Although TP has been marketed as a traditional Chinese medicine, its multi-organ toxicity prevents it from being widely used in clinical practice.
CONCLUSIONS: Triptolide, a biologically active natural product extracted from the root of Tripterygium wilfordii, has shown promising pharmacological effects, particularly as an anti-tumor agent. Currently, in anti-cancer research, more effort should be devoted to investigating effective anti-tumor targets and confirming the anti-tumor spectrum and clinical indications of novel anti-tumor pro-drugs. To apply TP appropriately, with high efficacy and low toxicity, the safety and non-toxic dose range for specific target organs and diseases should be determined, the altered pathways and mechanisms of exposure need to be clarified, and an early warning system for toxicity needs to be established. With further in-depth study of the efficacy and toxicity of TP, we believe that TP will become a promising multi-use drug with improved clinical efficacy and safety in the future.
Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Anti-tumor; Metabolism; Toxicity; Tripterygium wilfordii Hook. f.; Triptolide; Triptolide (PubChem CID: 107985)

Mesh:

Substances:

Year:  2014        PMID: 24933225     DOI: 10.1016/j.jep.2014.06.006

Source DB:  PubMed          Journal:  J Ethnopharmacol        ISSN: 0378-8741            Impact factor:   4.360


  90 in total

1.  Renal-targeting triptolide-glucosamine conjugate exhibits lower toxicity and superior efficacy in attenuation of ischemia/reperfusion renal injury in rats.

Authors:  Yu Fu; Qing Lin; Tao Gong; Xun Sun; Zhi-Rong Zhang
Journal:  Acta Pharmacol Sin       Date:  2016-07-11       Impact factor: 6.150

2.  Tripterygium glycosides induce premature ovarian failure in rats by promoting p53 phosphorylation and activating the serine/threonine kinase 11-p53-p21 signaling pathway.

Authors:  T E Liu; Lina Zhang; Suwei Wang; Chuan Chen; Jin Zheng
Journal:  Exp Ther Med       Date:  2015-05-18       Impact factor: 2.447

3.  Influence of Verapamil on Pharmacokinetics of Triptolide in Rats.

Authors:  Yichuan Zhang; Jin Li; Xiaolin Lei; Tianying Zhang; Guangxian Liu; Maohui Yang; Min Liu
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2016-08       Impact factor: 2.441

4.  Inhibitory Effects of Triptolide on Human Liver Cytochrome P450 Enzymes and P-Glycoprotein.

Authors:  Hanhua Zhang; Guangkui Ya; Hongbing Rui
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2017-02       Impact factor: 2.441

5.  Self-protection against triptolide-induced toxicity in human hepatic cells via Nrf2-ARE-NQO1 pathway.

Authors:  Ling-Ling Zhou; Cong Zhou; Xiao-Wen Liang; Zhe Feng; Zhang-Pu Liu; Hao-Lu Wang; Xue-Ping Zhou
Journal:  Chin J Integr Med       Date:  2017-05-18       Impact factor: 1.978

6.  Triptolide induces autophagy and apoptosis through ERK activation in human breast cancer MCF-7 cells.

Authors:  Huan Gao; Yue Zhang; Lei Dong; Xiao-Yu Qu; Li-Na Tao; Yue-Ming Zhang; Jing-Hui Zhai; Yan-Qing Song
Journal:  Exp Ther Med       Date:  2018-02-01       Impact factor: 2.447

7.  Activation of natural killer T cells contributes to triptolide-induced liver injury in mice.

Authors:  Xin-Zhi Wang; Ru-Feng Xue; Shen-Ye Zhang; Ya-Ting Zheng; Lu-Yong Zhang; Zhen-Zhou Jiang
Journal:  Acta Pharmacol Sin       Date:  2018-07-16       Impact factor: 6.150

Review 8.  HSF1 as a Cancer Biomarker and Therapeutic Target.

Authors:  Richard L Carpenter; Yesim Gökmen-Polar
Journal:  Curr Cancer Drug Targets       Date:  2019       Impact factor: 3.428

9.  Antitumor properties of triptolide: phenotype regulation of macrophage differentiation.

Authors:  Han Li; Liping Li; Huifang Mei; Guofeng Pan; Xinzhi Wang; Xin Huang; Tao Wang; Zhenzhou Jiang; Luyong Zhang; Lixin Sun
Journal:  Cancer Biol Ther       Date:  2019-10-30       Impact factor: 4.742

10.  Triptolide protects against white matter injury induced by chronic cerebral hypoperfusion in mice.

Authors:  Yu-Shan Wan; Yi You; Qian-Yun Ding; Yi-Xin Xu; Han Chen; Rong-Rong Wang; Yu-Wen Huang; Zhong Chen; Wei-Wei Hu; Lei Jiang
Journal:  Acta Pharmacol Sin       Date:  2021-04-06       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.